Rationale The use of benzodiazepines in treating anxiety symptoms in patients with posttraumatic stress disorder (PTSD) has been debated. Studies on other anxiety disorders have indicated changed sensitivity to GABA-A receptor active substances. Objective In the present study, we investigated the GABA receptor sensitivity in PTSD patients. Methods Injections of allopreganolone, diazepam, and flumazenil were carried out, each on separate occasions, in 10 drug naïve patients with PTSD compared to 10 healthy controls. Effects were measured in saccadic eye velocity (SEV) and in subjective ratings of sedation. Results The PTSD patients were less sensitive to allopregnanolone compared with healthy controls. This was seen as a significant difference in SEV between the groups (p=0.047). Further, the patients were less sensitive to diazepam, with a significant less increase in sedation compared to controls (p=0.027). After flumazenil injection, both patients and controls had a significant agonistic effect on SEV, leading to decreased SEV after injection. The patients also responded with an increase in sedation after flumazenil injection, while this was not seen in the controls. Conclusions Patients with PTSD have a changed sensitivity to GABA-A receptor active substances. As a consequence of this, benzodiazepines and other GABA-A receptor active compounds such as sleeping pills will be less useful for this group of patients.
Introduction
Posttraumatic stress disorder (PTSD) is a chronic anxiety disorder that follows after having experienced or witnessed a traumatic event, such as an accident, combat, physical attack, or rape. PTSD is characterized by persistent re-experiencing of the traumatic event, persistent avoidance of stimuli associated with the event, numbing of general responsiveness, and symptoms of increased arousal (American Psychiatric Association 1994) . These are all disabling symptoms causing a significant impairment in the victims' daily lives such that the term "a major public health issue" was used even some 40 years ago (Burgess and Holmstrom 1974) .
The mechanism behind the development of PTSD has been examined in numerous studies, with impairments in the HPA axis (Jones and Moller 2011; Yehuda and Seckl 2011) , levels of neuroactive steroids (Rasmusson et al. 2006; Pinna and Rasmusson 2012) , changes in CNS sensitivity and receptor concentration (Bremner et al. 2000) , and actual impairment on receptor level (Turkmen et al. 2011 ), all having been named when trying to describe the pathophysiology of the disorder. Much attention has been given to the GABA-A receptor in disorders such as panic and anxiety disorders (Roy-Byrne et al. 1990 ), premenstrual dysphoric disorder (Backstrom et al. 2014; Sundstrom et al. 1997; , burnout syndrome (Backstrom et al. 2013) , and depression (Mohler 2012) .
The GABA receptor is the most important inhibitory receptor in the nervous system, and activation by a positive modulator causes sedation, amnesia, and ataxia, while activation with an inverse agonist or antagonist causes arousal, restlessness, insomnia, and exaggerated reactivity (Sigel and Steinmann 2012) . As the latter symptoms are all described in PTSD patients, it would be of interest to investigate the GABA-A receptor function in PTSD patients.
GABA-A receptor modulators (e.g., benzodiazepines) are still used for anxiety and insomnia disorder. The use of benzodiazepines in treating anxiety and sleeping disturbances in PTSD patients has been debated. Because of reports of several side effects as well as benzodiazepine's lack of effect in this patient group, they have been proposed to be contraindicated (Lund et al. 2013 ). However, the actual cause of these drug effects is still unknown. An abnormality in the benzodiazepine receptor sensitivity in patients with panic disorder was suggested by Roy-Byrne et al. (1990) , who investigated the effect of increasing doses of intravenous diazepam on saccadic eye velocity (SEV), memory, and self-rated sedation in patients with panic disorder. The patients were less sensitive than controls to diazepam when using SEV as the dependent measure. The authors therefore suggest a subsensitivity of the GABA-benzodiazepine receptor complex. To our knowledge, apart from the benzodiazepine receptor (Bremner et al. 2000) , the GABA-A receptor function has not been investigated in patients with PTSD. One way of measuring the GABA-A receptor function is by measuring the SEV. This technique is a validated and objective way to estimate sensitivity to GABA-A receptor drugs in the neural circuits controlling the saccade and has been used by Bäckström and colleagues in several studies (Backstrom et al. 2013; Sundstrom et al. 1997; Timby et al. 2006) . Different subunits of the GABA-A receptor have different sensitivity to different drugs. The GABA-A receptor subtype α4, β, δ is hypersensitive to the positive GABA-A receptor modulating steroid allopregnanolone, while it is insensitive to benzodiazepine. Flumazenil, on the other hand, is known to change its action from being a benzodiazepine antagonist or inert compound to become an agonist having a benzodiazepine-like effect on its own in GABA-A receptor subtype α4, β, δ. Therefore, these three drugs are suitable to use in challenge tests to bring to light whether there are changes in GABA-A receptor sensitivity and relate the effect of compounds to possible changes in GABA-A receptor subtypes in a disorder. In a previous study on female patients with burn out syndrome, signs of increased sensitivity to allopregnanolone and changed action of flumazenil suggesting an up-regulation of GABA-A receptor subtype α4, β, δ were found (Backstrom et al. 2013) .
The aim of the present study was to investigate the GABA receptor sensitivity in PTSD patients. This was done by testing the effect of injections of allopreganolone, diazepam, and flumazenil, each on separate occasions, in patients with PTSD compared to healthy controls. Effects were measured in SEV and in subjective ratings of sedation. Our hypothesis was that PTSD patients have a changed sensitivity to GABA-A receptor active substances. More precisely, we hypothesized that PTSD patients have an increased sensitivity to allopregnanolone and a decreased sensitivity to diazepam compared to controls. Further, we hypothesized that PTSD patients would experience an agonistic effect from flumazenil.
Material and methods

Participants
The patients were recruited from the Emergency Clinic for Raped Women, Stockholm South Hospital, with a minimum of 6 months after the most recent rape. The patients were all diagnosed as having posttraumatic stress disorder (PTSD) according to the Diagnostic and Statistical Manual of Mental Disorder (DSM-IV, F43.1). PTSD was diagnosed using the Structured Clinical Interview for DSM IV (SCID-I). The clinical interviewers were all female therapists trained and well familiar with this instrument. Controls were healthy female volunteers recruited through advertisement. Before entering the study, both patients and controls received written and oral information about the study and had to sign a written consent.
The study was approved by the local medical ethics committee in Stockholm (2011/852-31/3 and 2012/492-32) and by the Medical Products Agency of Sweden.
Inclusion criteria Patients had to fulfill all six criteria for PTSD according to the DSM-IV. They also had to have high scores on the Stanford Acute Stress Reaction Questionnaire (SASRQ) (>80 out of 150 points). Controls all had to score 0 out of possible 6 points on the SCID-I interview and have low scores on the SASRQ questionnaire (<10 out of 150 points). These scales are clarified later in the text. Further requirements for both patients and controls consisted of being age 18-40 years old, having fairly regular menstruations, not taking any hormonal contraceptives, and being in the follicular phase (days 6-12) of the menstruation cycle at the time of the challenge.
Exclusion criteria Subjects were excluded if they had a history of psychosis, major or bipolar depression, alcohol or substance use, neurological disease, endocrine disease, polycystic ovarian syndrome (PCOS), premenstrual dysphoric disorder (PMDD), and being pregnant or planning to become pregnant within 3 months after the last challenge. Further, they were excluded if they were taking any daily medications such as antidepressants, anxiolytics, or sedative drugs. Participants were also excluded from the study if they reported having been taking any benzodiazepines within 3 months before the challenge (including any occasional medication) and alcohol within 72 h before the challenge. All data on diseases and psychiatric disorders were based on self-reports. Both patients and controls also received a medical screening consisting of a physical examination and test of thyroid and liver function.
Saccadic eye velocity (SEV)
Saccadic eye movement velocity was measured using a noninvasive videonystagmographic device (Ulmer VNG, Atos Medical AB®). The device has an open mask (Visio 50) for rapid eye movements with a camera that gives binocular analysis. The model allows unlimited calibration in horizontal movements and +90/−20°vertically and has an accuracy of 0.1. The camera sensor is mounted on a rigid helmet. Before the start of the study, the camera sensor was adjusted so that it was positioned several centimeters from the eyes, at the level of the tip of the nose, and pointed up toward the pupil in mid position. The target was at a 115-cm distance from the eye and consisted of a white light on a black background. Participants were instructed to watch the white light and try not to anticipate where the next target would be. Calibration was achieved by asking the participant to fixate targets at 20 and 30 right and left, as well as above and below the center before each series of measurements. Recalibration minimized error due to head movements. After calibration, measurements were conducted using a target moving in rapid steps back and forth in the horizontal plane from the left of center to the right of center at a constant velocity. The subject was asked to move the eye to the new point and fixate on that. The speed of the eye movement in degree/s was calculated by a computer. Saccades of 20°were used in this study. Eye position data were stored and displayed on the computer, and data from both eyes were combined. The peak velocity was calculated and displayed for each saccade.
Visual analog ratings of sedation
Subjective ratings of sedation were done by the test persons using a visual analog scale (VAS) (McCormack et al. 1988 ). The scale measured from 0 to 10 cm, where 0 represented complete absence of sleepiness and 10 represented nearly falling asleep. The ratings were made at baseline as well as at the same time points as the saccadic eye measurements.
Diazepam solution
Stesolid® Novum (Actavis) 5 mg/ml in a dose of 0.1 mg/kg was used in the diazepam challenge. The injection was given intravenously over a span of 0.5 min. This dose was chosen based on earlier experience with the effect of diazepam on SEV (Sundstrom et al. 1997 ).
Flumazenil solution
Flumazenil (Fresenius Kabi) 0.1 mg/ml in a dose of 0.018 mg/kg was used in the flumazenil challenge. The injection was given intravenously over a span of 1.5 min. This dose was chosen based on previous data (Savic et al. 1991 ) that 1.5 mg flumazenil occupies about 55 % of the benzodiazepine receptors but does not have any behavioral side effects.
Allopregnanolone solution
The allopregnanolone solution was prepared at a maximum of 7 days before actual use by APL (Apotek, Produktion & Laboratorier AB, Box 5071, 141 05 Kungens Kurva, Sweden). The intravenous solution was formulated with purified allopregnanolone, UC 1009 (Umecrine AB, Box 7984, 907 19 Umeå, Sweden), with 15 mg allopregnanolone dissolved in 100 ml albumin solution (Pharmacia, Stockholm, Sweden, 200 mg/ml) using an ultrasound bath. The solution contained 0.128± 0.001 mg/ml (mean ± SEM) allopregnanolone. The allopregnanolone concentration of each batch of solution was determined using an HPLC technique: for details see (Turkmen et al. 2011 ). Allopregnanolone was given as an intravenous injection in a dose of 0.05 mg/kg.
Allopregnanolone analysis
The allopregnanolone analysis method has been described in detail earlier (Timby et al. 2006) . Briefly, the samples (0.4 ml) were extracted with diethyl ether (Merck KGaA, Damstadt, Germany). Allopregnanolone was separated from cross-reacting steroids with celite chromatography. Allopregnanolone was measured by RIA using a polyclonal rabbit antiserum raised against 3α-hydroxy-20-oxo-5α-pregnan-11-yl-carboxymethyl ether coupled to bovine serum albumin, provided by RH Purdy (The Scripps Research Institute, La Jolla,CA,USA) (Purdy et al. 1990 ). The sensitivity of the assay was 25 pg. The intra-assay coefficient of variation was 6.5 %, and the inter-assay coefficient of variation was 8.5 %.
Psychometric scales
The PTSD Module of the Structured Clinical Interview for DSM-IV (SCID-I) was used to establish current PTSD.
The Beck Depression Inventory (Beck and Steer 1996) is a 21-item inventory measuring depressive mood and vegetative symptoms of depression. Cutoff points for the sum scores were 0-9 (no depression), 10-16 (mild depression), 17-29 (moderate depression), and scores ≥30 (severe depression). Internal consistency according to Cronbach's alpha was 0.90.
The Stanford Acute Stress Reaction Questionnaire (SASRQ) (Cardena et al. 2000 ) is a 30-item self-report instrument with a Likert-type scale (0-5) with a total score between 0 and 150. The questionnaire is mainly used in diagnosis of acute stress disorder (ASD) but can also be used for measuring PTSD symptom severity by making a score of PTSD symptoms. The internal consistency according to Cronbach's alpha was 0.92 for the whole questionnaire.
The Anxiety Sensitivity Index (ASI) measures fear for panic or anxiety (Reiss et al. 1986 ). The overall score ranges from 0 to 64 and a mean score of 19.1 were reported for a normal population (Peterson and Reiss, 1992) .
The State-Trait Anxiety Inventory (STAI) has a total score of 20 to 80 points. A total score below 40 indicates low, between 40 and 59 moderate, and 60 or more severe state of anxiety (Spielberger et al. 1970) .
The State Anxiety and Discomfort Scale (SADS) range from 0 to 5 and measures changes in anxiety level when used repeatedly.
Study protocol
The challenges were performed at the Emergency Clinic for Raped Women, Stockholm South Hospital, in Stockholm. The SCID-I interview, SASRQ questionnaire, and Beck Depression scale were all administrated at the time of inclusion in both patients and controls. The participants arrived at either 8 a.m. or 1 p.m., and each challenge took about 3.5 h to perform. Participants sat in a large comfortable chair with wide armrests and support. An intravenous catheter was inserted in each forearm, one for drug administration and one for drawing blood samples. Baseline blood samples for allopregnanolone were drawn before the allopregnanolone challenge. Initial scoring of anxiety and mood symptoms (ASI, STAI, and SADS) was done before the start of the experiment, and the scales were used as safety parameters to catch any adverse events. The challenges with diazepam, flumazenil, and allopregnanolone were performed in mentioned order and were all done at separate occasions with usually 1 month in between, but always at a minimum of 3 days in between. All challenges were done in follicular phase, when allopregnanolone levels are known to be generally low (Nyberg et al. 2007 ). The substance was not blinded either for the researcher or the participant. Ratings of subjective sedation as well as SEV were measured at baseline before an IV injection of one of the three test substances (allopregnanolone, diazepam, or flumazenil). After the injection, SEV and sedation were measured after 5, 13, 18, 25, 30, 45, 60, 120 , and 180 min. Blood samples for allopregnanolone concentrations as well as SADS rating were taken at 5, 18, 30, 45, 60, 120, and 180 min. All participants then rated their anxiety symptoms on PSS, STAI, and SADS at home 24 h after the challenge. Statistics SEV parameters and VAS self-rating scores were calculated as the difference from baseline at each time point, in other words, delta degrees/s and delta sedation scores. The SEV parameters were analyzed using analyses of variance (ANOVA) with repeated measures and the least significant difference (LSD) test as a post hoc test. Differences in baseline demographic data, allopregnanolone concentrations, psychometric scales, and sedation between the groups were calculated with the Mann-Whitney U test. The SPSS statistical package (version 22.0) was used for all statistical analyses. Variables were considered significant if the Wald test resulted in a p<0.05.
Results
Demographic data and subjective ratings
The demographic data and subjective scoring at baseline of the PTSD patients and controls are presented in Table 1 . The controls were matched regarding age, BMI, and cycle day. Significant differences in subjective scoring were seen in all scales between patients and controls.
A total of 12 patients and 16 controls completed a total of 57 challenges. Ten patients and 10 controls were meant to be included in each challenge. However, in the diazepam and flumazenil challenge, 9 patients but 10 controls were included. In the allopregnanolone challenge, 10 participants in each group were included; however, one control was excluded because of technical problems during the challenge.
Sedation
After injection of allopregnanolone, controls showed an increase in sedation (p=0.011, Fig. 1, allopregnanolone) , while PTSD patients showed a tendency toward increased sedation, though it was not significant. There was no significant difference between the groups.
After injection of diazepam, both groups showed a significant increase in sedation (Fig. 1, diazepam) . There was also a significant difference between the groups where the patients showed less effect compared to controls (p=0.027).
After injection of flumazenil, the patients showed an increase in sedation (p=0.010, Fig. 1, flumazenil) , while the controls did not show any effect of flumazenil. However, there was no significant difference between the two groups regarding sedation.
SEV
After injection of allopregnanolone, both groups showed a significant decrease in SEV (PTSD p=0.001, controls p= 0.005). Except for the first 5 min after injection, there was a significant difference between the two groups in response (see Fig. 2 , allopregnanolone). Patients responded less than controls (a=p=0.047). If exploring the response 18 min after the injection, the difference was even greater (a=p=0.038). When calculating the area under the curve (AUC) for SEV from before injection (−5 min) to 180 min after the injection, there was also a significant difference (Mann-Whitney U test) between the groups (p=0.017) After injection of diazepam, both patients and controls answered with a significant decrease in SEV (Fig. 2, diazepam) . However, there was no significant difference in reaction between the two groups.
After injection of flumazenil, we surprisingly saw a decrease in SEV in both groups (Fig. 2, flumazenil) . This reaction was similar to what was seen after injection of diazepam. There was no significant difference in reaction between the two groups.
Latency
The latency of the onset of the eye movement after change of target showed no changes during the challenge test in either of the groups and no difference between the groups (data not shown).
Allopregnanolone concentrations
Baseline concentrations of allopregnanolone were not different between the two groups (Table 1) . Patients and controls also showed the same concentration curves after allopregnanolone injection (Fig. 3) . Because of the similar concentrations, the SEV and sedation reactions in the two groups did not have to be adjusted for actual concentration.
Anxiety scores
Subjective scorings of SADS, PSS, and STAI before and after each challenge in both groups are presented in Table 2 . There was no adverse effect detected in any of the groups concerning the scores in these three scales. One of the controls reported negative mood the same night after the allopregnanolone challenge, and one control reported negative mood the same night after the diazepam challenge. In both cases, the mood changes had normalized after 24 h. No self-reported mood changes occurred during or after flumazenil injection in any of the groups. By measuring SADS scores throughout the challenges, we saw that there were no negative reactions caused by any of the three substances. However, patients generally scored higher than the controls.
Discussion
Our first hypothesis that PTSD patients would be more sensitive to allopregnanolone was not confirmed. In the study of burnout patients (Backstrom et al. 2013) , the patients had an increased sensitivity to allopregnanolone that was suggested to be caused by an up-regulation of the α4, β, δ subunit of the GABA-A receptor. As these results were not replicated in the present study, an up-regulation of the α4, β, δ GABA receptor is unlikely in the present group of PTSD patients. Our finding of a reduced sensitivity to allopregnanolone is more in line with the results from the studies with benzodiazepines on patients with premenstrual dysphoric disorders (Nyberg et al. 2007; Sundstrom et al. 1997 ) and panic disorder (Roy-Byrne et al. 1990 ), where the patients had a decreased sensitivity. This was suggested to be caused by an acquired chronic allopregnanolone tolerance. As stress causes increased levels of allopregnanolone (Droogleever Fortuyn et al. 2004 ), a tolerance is very likely to be present also in patients with PTSD.
Our second hypothesis that PTSD patients would have a reduced sensitivity to diazepam was partly confirmed. As mentioned earlier, there was no significant difference in the response to diazepam injection regarding SEV between the patients and controls; however, patients became significantly less sedated. The α1, γ subunit of the GABA-A receptor has been pointed out in the regulation of sedation (Korpi and Sinkkonen 2006) . Thus, our results could be suggested to be caused by the patients also having a tolerance in this system. Such increases in tolerance can also be seen after repeated benzodiazepine or alcohol intake. We know that there is a high comorbidity between PTSD and substance abuse (Kessler et al. 1995; Kilpatrick et al. 2003; Macdonald et al. 2010) ; however, as substance abuse was part of the exclusion criteria in this study, it is believed not to be the explanation.
The third hypothesis that PTSD patients would experience an agonistic effect of flumazenil was confirmed. However, we made the surprising finding that controls also experienced an agonistic effect from flumazenil, responding with decreased SEV after injection. This is in contrast to what was found in controls in the burnout patient study (Backstrom et al. 2013) where flumazenil had no effect on the controls. However, in that study, flumazenil was given 35 min after an injection of allopregnanolone, which makes it more difficult to compare the results.
Further, we saw that baseline concentrations of allopregnanolone did not differ between patients and controls. This is contradictory to what has been found in earlier studies showing that PTSD patients have decreased levels of allopregnanolone (Rasmusson et al. 2006) . We also saw that concentrations of allopregnanolone after injection and measured repeatedly during the challenge had no significant differences between the groups. This was expected, as the amount of allopregnanolone given was in relation to the subjects' weight. However, this also suggests that patients and controls have the same metabolism of allopregnanolone. The lack of difference in allopregnanolone levels between the groups in this study could of course be caused by the relatively small number of participants. The half-life of flumazenil and allopregnanolone (e.g., 40-80 and 40-50 min, respectively) has to be taken into account when interpreting the results from the later time points of the challenges because of decreasing serum concentrations. However, the half-life of these steroids in the brain is not known. Further, the effect of flumazenil on sedation in the patients came quickly, and even though it decreased over time, it stayed increased throughout the challenge. Therefore, the 3-hour observation time was kept, and also, to be able to compare the three challenges.
Finally, we saw that the patients scored generally higher than controls on the subjective anxiety scales before, after, and during the challenges. However, none of the drugs led to any significant changes in anxiety during or after the challenges. This is contradictory to what was found in the study by (Nutt et al. 1990 ) that flumazenil causes increased anxiety in panic disorder patients and that flumazenil induces panic responses in PMDD patients (Le Melledo et al. 2000) . Our results, which do not show these side effects in PTSD patients, are in line with the findings of Randall and colleagues (Randall et al. 1995) .
There are some clinical implications for our findings. As mentioned earlier, the use of benzodiazepines have been questioned because of their lack of effect as well as causing impaired impulse control in patients with PTSD. Further, some studies have shown an increase in PTSD prevalence after traumas when benzodiazepines are given (Wade et al. 2013) . Our results that diazepam had a significantly lower effect on sedation in PTSD patients than in controls caused by a possible tolerance in the receptor could be one explanation for these effects. Thus, our data confirm the suspicion that medication with benzodiazepines for PTSD is counterproductive since they are ineffective. Another interesting implication of our results could be in the discussion about the use of SSRIs in PTSD patients. SSRIs have been used as the drug of choice in these patients, and their positive effects are well documented (Stein et al. 2000) . However, the actual mechanism of SSRI effects is still not fully understood. In a study of PMDD patients , the patient group was found to have a decreased sensitivity to the allopregnanolone isomer pregnanolone. When these patients were given SSRIs, they normalized their sensitivity to pregnanolone. One possible explanation for the SSRI positive effect on PTSD patients, therefore, might be an effect of changes in the GABA-A receptor rather than the drug causing increased serotonin levels. This has to be followed up in further studies. The present study has some limitations. The sample size was relatively small, something that might reduce generalization. However, as we used a well-defined group of patients that all had to be drug naïve, the number of eligible patients decreased drastically. The inclusion was troublesome as majority of patients with PTSD either medicate with SSRIs, anxiolytics, or sedative drugs. Further, many patients were excluded because of self-medication with alcohol. However, as we did not use any drug screening on the morning of the challenge, any absence from self-medication was solely based on the participants' reports. Another possible limitation could be that there was no placebo arm. However, several earlier studies with placebo injections over prolonged time have not shown any deviation in SEV over the time frame used in this study (Sundstrom et al. 1997; ). Therefore, a placebo arm was not considered necessary as the demand on the subjects were high with the three different substances. Finally, measurements of sedation were solely based on the participants' subjective ratings.
Conclusions
Women with PTSD have a changed sensitivity to GABA-A receptor active substances. As a consequence of this, benzodiazepines and other GABA-A receptor active compounds such as sleeping pills will be less useful for this group of patients. If this is a result from a chronic exposure of neuroactive steroids during a long period of time, it could be one part of the explanation of the development of PTSD. An impairment in the receptor will cause a malfunction of the "mental brakes," leading to repeated flashbacks, nightmares, concentration problems, increased anxiety, and other related symptoms. In the PTSD patient, this will lead to increased reexperience of the traumatic memories and feelings.
